Home ▸ News

Ischemix, Inc. Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

September 30, 2015

Ischemix, Inc., a clinical-stage pharmaceutical company focused on hospital-acquired kidney and cardiac injury, announced today that it has completed enrollment in its Phase 2 CARIN trial for prevention of contrast-induced acute kidney injury (CI-AKI) in patients entering the cardiac catheterization lab. Additionally, CARIN is designed to confirm Ischemix' previous successful Phase 2 results in the use of CMX-2043 for prevention of periprocedural cardiac injury in patients receiving cardiac stents (percutaneous coronary intervention or PCI). A total of 361 subjects have been enrolled in the CARIN trial. With the last subject enrolled completing follow-up in mid-December, complete data from the trial is projected to be available in the first quarter of 2016.

David A. DeWahl, Jr., President and CEO of Ischemix said "We are very grateful for the participation of the 31 sites in the US and Canada that enrolled subjects in the trial. We expect that receipt of successful results from the trial would enable us to secure the resources to continue our development plan for CMX-2043."

CARIN is a randomized, double-blind, placebo-controlled trial being conducted to assess the efficacy of CMX-2043 in the prevention of renal and cardiac injury associated with coronary angiography in patients with acute coronary syndrome (ACS) or non-ACS patients undergoing a high risk elective coronary angiography. The primary endpoint of the trial is the prevention of contrast-induced acute kidney injury (CI-AKI). Secondary endpoints include reduction in renal injury as determined by kidney biomarkers, incidence of major adverse cardiac events (MACE) or major adverse kidney events (MAKE) or other clinical complications, reduction in cardiac injury as determined by cardiac biomarkers and reduction in the incidence of Type 4a MI.

"CMX-2043, if ultimately approved for use in prevention of CI-AKI, would address a significant void in the critical care therapeutics marketplace." said Dr. Geoffrey E. Clark, Chief Medical Officer of the Company. "There are no drug therapies currently available to prevent or treat CI-AKI."

Latest News

August, 2023

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

July 7, 2021

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

March 25, 2019

Novel Compound for Treatment of Traumatic Brain Injury (TBI) Demonstrates Positive Results in a Preclinical Study

April 4, 2016

Ischemix Announces Results of Its Phase 2 CARIN Trial

January 5, 2016

Ischemix, Inc. to Present at Biotech Showcase™ on January 13, 2016

December 9, 2015

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

September 30, 2015

Ischemix, Inc. Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

August 12, 2015

Ischemix Elects Peter G. Milner, MD to Board of Directors

May 19, 2015

Safety Review Committee for CARIN Trial recommends Phase 2a study to continue as planned

March 24, 2015

Ischemix Appoints Clinical Trial Liaison

June 26, 2014

Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Inury

January 9, 2013

Ischemix Appoints new Chief Executive Officer

June 17, 2011

Ischemix Completes Phase 2a Clinical Trial

March 2, 2011

Ischemix Granted Composition of Matter Patent for CMX-2043

March 9, 2010

Ischemix Initiates Phase 2a Clinical Trial

August 13, 2007

Ischemix Completes Phase 1 Clinical Trial

April 5, 2007

Ischemix Initiates Clinical Development